VistaGen Therapeutics Company Presentation

www.vistagen.com 33 AV-101 and Adjunctive Probenecid Recent preclinical data demonstrate substantial increases in rodent brain concentrations of both AV-101 (4-Cl-KYN) and 7-Cl-KYNA Probenecid increases AV-101 (4-Cl-KYN) brain levels by ~ 7-fold Probenecid increases 7-Cl-KYNA brain levels by > 35-fold Dickens, D., (2019, December). Drug transporters at the blood-brain barrier as targets for personalised CNS therapeutics. Speaker at British Pharmacological Society, Pharmacology 2019, Edinburgh, UK,